FDA knocks Bausch for misleading promotion of psoriasis drug on Lifetime show

The US Food and Drug Administration’s Office of Prescription Drug Promotion (OPDP) sent Bausch Health an untitled letter for making misleading statements about its plaque psoriasis lotion Doubrii (halobetasol propionate and tazarotene) on Montel Williams’ Lifetime morning show “The Balancing Act.” The agency said the company exaggerated claims and failed to adequately inform people about the product’s risks.